ORIC Pharmaceuticals Announces Inducement Grants
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC), a pioneering clinical-stage oncology company headquartered in South San Francisco and San Diego, has made noteworthy moves to bolster its employee structure. Recently, it announced the granting of 18,400 non-qualified stock options alongside 3,000 restricted stock units on a specified grant date. These inducements were offered to a new non-executive employee who joined the company in October.
Details of the Inducement Grants
The inducement grants awarded by ORIC are part of the company's 2022 Inducement Equity Incentive Plan. These grants were issued under specific conditions to ensure the recipient's continued employment through each geared vesting date. As stipulated, the stock options come with an exercise price reflective of ORIC's common stock closing price on the designated grant date.
Vesting Schedule for the Inducement Grants
According to the plan, 25% of the stock options are set to vest one year following the grant date, with the remaining shares vesting in monthly increments thereafter. Additionally, the restricted stock units will vest one-third on each of the first three anniversaries of the grant date. All these inducements are subject to the defined terms of the stock option and restricted stock unit agreements, aligning with the established incentive plan.
Compliance with Nasdaq Regulations
This move by ORIC Pharmaceuticals was not just a corporate strategy but also a compliance measure. The inducement grants received approval from ORIC's Compensation Committee as mandated by Nasdaq Rule 5635(c)(4). This rule is crucial as it ensures that such grants are a significant incentive for the employees, fostering a culture of retention and commitment.
About ORIC Pharmaceuticals
Founded with the mission of improving patients' lives through innovative treatments, ORIC Pharmaceuticals is dedicated to addressing challenges in cancer therapy related to resistance mechanisms. Their clinical portfolio includes ORIC-944, which targets prostate cancer by inhibiting the polycomb repressive complex 2 (PRC2). Furthermore, they are developing enozertinib (ORIC-114), specifically aimed at various genetically defined cancers that exhibit specific mutations.
Future Developments
As ORIC Pharmaceuticals continues to evolve, the importance of such inducement grants can’t be understated. They represent a strategic effort not only to attract talent but also to retain valuable employees dedicated to the company's vision. This aligns with ORIC’s goal of fostering a robust workplace culture that advances cancer treatment research and development.
Contact Information
For more information about ORIC and its initiatives, you can reach out to Dominic Piscitelli, Chief Financial Officer, via email at dominic.piscitelli@oricpharma.com or at info@oricpharma.com.
Frequently Asked Questions
What are the inducement grants awarded by ORIC Pharmaceuticals?
The inducement grants consist of non-qualified stock options and restricted stock units, aimed at incentivizing employee retention and engagement.
Who approved the inducement grants for ORIC Pharmaceuticals?
The grants were approved by ORIC's Compensation Committee in compliance with Nasdaq regulations.
How does the vesting schedule work for the inducement grants?
25% of the stock options vest one year after the grant date, with the rest vesting monthly thereafter, and restricted stock units vest in one-third increments over three years.
What is ORIC Pharmaceuticals' mission?
ORIC Pharmaceuticals is committed to improving patient outcomes by developing innovative cancer therapies that overcome resistance mechanisms.
How can I get in touch with ORIC Pharmaceuticals?
You can contact the Chief Financial Officer, Dominic Piscitelli, via email for inquiries related to ORIC.
